CFD+CD14+ monocytes: potential pathogenic subset in myasthenia gravis uncovered by multi-omics integration and machine learning analysis

Objective:

To identify and characterize a novel pathogenic subset of CD14+ monocytes in Myasthenia Gravis (MG) using multi-omics and machine learning approaches, highlighting their potential as therapeutic targets.

Key Findings:

• Increased proportion of CD14+ monocytes in MG patients with significant transcriptomic reprogramming, indicating a shift in immune response.
• CD14+ monocytes showed higher TWAS activity compared to other cell types, suggesting their central role in MG pathology.
• Identified six robust signature genes, including CFD, associated with high TWAS activity in MG, which may serve as biomarkers.
• CFD+CD14+ monocytes exhibited enhanced intercellular communication and functional plasticity, potentially influencing disease progression.

Interpretation:

The study highlights the critical role of CFD+CD14+ monocytes in the pathogenesis of MG, suggesting they may be key players in the disease's immunological mechanisms and potential therapeutic targets.

Limitations:

• The study relies on data from public repositories, which may limit the generalizability of findings and introduce biases.
• Further validation in larger cohorts is needed to confirm the identified monocyte subset's role in MG and its therapeutic implications.

Conclusion:

This research provides novel insights into the immunopathology of MG, emphasizing the importance of CFD+CD14+ monocytes as potential therapeutic targets, paving the way for future treatment strategies.